Clinical trials: Acquired Immune Deficiency Syndrome
Human Immunodeficiency Virus
Peers Plus Mobile App for Treatment in HIV
This study called "Peers plus mobile App for Treatment in HIV (PATH)" is a two-arm randomized controlled trial (RCT) evaluating the efficacy of an intervention that combines peer navigation and mobile health (mHealth) technology…
- Trial name
- PATH (NCT05427318)
- Testing
- PATH
- Where
- United States
- Volunteers
- 309 people, healthy volunteers welcome
- Sponsor
- San Diego State University
Hiv
Tenofovir Adherence to Rapidly Guide and Evaluate PrEP and HIV Therapy
Adherence to antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) are critical to the success of HIV treatment and therapeutic prevention.
- Trial name
- TARGET (NCT03012607)
- Testing
- Truvada
- Where
- Thailand
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Washington
Progressive Multifocal Leukoencephalopathy
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
Background: Progressive multifocal leukoencephalopathy (PML) is a severe viral infection of the brain. It is caused by JC virus.
- Trial name
- NCT01730131
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Tuberculosis, HIV/AIDS
TB Reduction Through ART and TB Screening Project
Tuberculosis (TB) has overtaken HIV as the leading infectious cause of death worldwide and requires a major policy shift for it to be controlled in line with the WHO Stop-TB goal to "end TB".
- Trial name
- TREATS (NCT03739736)
- Testing
- Combination of TB/HIV prevention activities (arm A), Combination of TB/HIV prevention activities (arm B), Standard of care (arm C)
- Where
- 2 sites in South Africa, Zambia
- Volunteers
- 4,200 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
HIV/AIDS, STI
MAKASI Intervention for African and Caribbean Migrants' Empowerment in Sexual Health in Paris Greater Area
Background. Immigrants from Sub-Saharan Africa are the second group most affected by HIV in France. Part of these HIV infections occurred after arrival in France, in relation to social hardships.
- Trial name
- MAKASI (NCT04468724)
- Testing
- MAKASI
- Where
- France
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV/AIDS, Infant Morbidity
Assessing the Feasibility, Acceptability and Effects Of HIV Birth Testing In Maternity Settings In Zimbabwe
This study aims to assess the feasibility and, acceptability and effects of implementing HIV testing at birth testing using point-of-care (POC) HIV nucleic acid testing (NAT) in maternity settings.
- Conditions
- HIV/AIDS, Infant Morbidity, Perinatal HIV Infection, HIV Infections
- Trial name
- NCT04206241
- Testing
- Point of care early infant diagnosis (POC EID)
- Where
- 10 sites in Zimbabwe
- Volunteers
- 278,833 people, healthy volunteers welcome
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
Infection, Human Immunodeficiency Virus
Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations
Dolutegravir (DTG) and lamivudine (3TC) are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
- Trial name
- NCT02738931
- Testing
- Dolutegravir 50 mg tablet, Lamivudine 300 mg tablet, Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
AIDS, HIV Infections
Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers
GSK has constructed a new HIV immunogen comprised of conserved parts of the HIV virus (gag, pol and nef). The principal objectives of this study are to evaluate the reactogenicity and safety of this candidate vaccine with or…
- Trial name
- NCT00434512
- Testing
- HIV vaccine 732461
- Where
- Belgium
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV-1-infection, Hepatitis C, Chronic
Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy
The study hypothesis is to determine the feasibility of switching HIV-HCV co-infected patients receiving methadone or buprenorphine/naloxone as opioid substitution therapy with suppressed HIV RNA viral load on current…
- Conditions
- HIV-1-infection, Hepatitis C, Chronic, Methadone Dependence, Opioid Dependence
- Trial name
- NCT03549312
- Testing
- Genvoya, Epclusa, Biktarvy
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Saskatchewan Health Authority - Regina Area
Sexually Transmitted Infection, Hiv
A Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women: IMARA SA
Programs which go beyond individual-level behavior change to reduce HIV and STI infections among adolescent girls and young women in sub-Saharan Africa are essential to meet global HIV targets.
- Trial name
- IMARA-SA pilot (NCT05504954)
- Testing
- IMARA-SA (intervention group), Health promotion control group
- Where
- South Africa
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Transgender Women, HIV/AIDS
Effects of Gender-Affirming Hormone Therapy Among Transgender Women
In this study, investigators plan to evaluate the cardiometabolic effects of initiating gender-affirming hormone therapy among transgender women with and without HIV.
- Conditions
- Transgender Women, HIV/AIDS, Cardiovascular Diseases, Metabolic Disease
- Trial name
- NCT04128488
- Testing
- Abdominal MR Imaging, Cardiac MRI/MRS, Oral Glucose Tolerance Testing
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Human Immunodeficiency Virus
Plan and Pledge, HIV Self-testing in South Africa
The Plan and Pledge pilot will incorporate behavioral economics approaches (nudges) into the pre-existing STAR self-test fixed-site distribution program, implemented by Wits Reproductive Health and HIV Institute (Wits RHI) at the…
- Trial name
- NCT03898557
- Testing
- Provision of HIV self-test with Commitment and planning prompts, Provision of HIV self-test
- Where
- United States
- Volunteers
- 1,479 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Allergic Rhinitis, Asthma
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
The specific aim of this proposed project is to implement a standard process for integrating MedlinePlus health information prescriptions into the clinic workflow.
- Conditions
- Allergic Rhinitis, Asthma, Back Pain, Benign Prostatic Hypertrophy
- Trial name
- NCT00634608
- Testing
- Health Information Prescription
- Where
- United States
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Infections, Streptococcal
Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.
The purposes of this study: To evaluate the immunogenicity, safety and reactogenicity of pneumococcal vaccine GSK1024850A in HIV infected infants, HIV exposed uninfected infants and HIV unexposed uninfected infants following a…
- Trial name
- NCT00829010
- Testing
- Pneumococcal vaccine GSK1024850A, Tritanrix-HepB/Hib, measles
- Where
- South Africa
- Volunteers
- 489 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infection, Human Immunodeficiency Virus
Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects
This study will be a phase 1, open label, parallel group, three period crossover study to evaluate the effect of dolutegravir (DTG) on the steady state pharmacokinetics of metformin and on the safety and tolerability of…
- Trial name
- NCT02064374
- Testing
- Metformin 500 mg q12h, Dolutegravir 50 mg q24h, Dolutegravir 50 mg q12h
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV/AIDS
Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS
The primary objective of the proposed phase I trial is to evaluate the safety and tolerability of DNA-HIV-PT123 and AIDSVAX®B/E combination regimen.
- Trial name
- EV06 (NCT02376582)
- Testing
- DNA, AIDSVAX B/E
- Where
- 2 sites in Uganda
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- EuroVacc Foundation
HIV Infections
Family Access to Care Study (FACS)
The purpose of this study is to find ways to get services to families living with HIV. New services for families living with HIV have been tried in places around the country. They seem to benefit many families.
- Trial name
- NCT00582218
- Where
- United States
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
HIV Infections, HIV/AIDS
Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP
This is a randomized clinical trial of doxycycline post-exposure prophylaxis (dPEP) to reduce bacterial STIs among Kenyan women taking pre-exposure prophylaxis (PrEP).
- Conditions
- HIV Infections, HIV/AIDS, Neisseria Gonorrheae Infection, Chlamydia Trachomatis Infection
- Trial name
- dPEP-KE (NCT04050540)
- Testing
- Doxycycline
- Where
- Kenya
- Volunteers
- 449 people, healthy volunteers welcome
- Sponsor
- University of Washington
Aging, Hiv
2nd AC+: New Village Model
This study evaluates implementation of the Village Model to support older people living with HIV.
- Conditions
- Aging, Hiv, Loneliness, Social Isolation
- Trial name
- 2nd AC+ (NCT04323176)
- Testing
- Village Model implementation
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Human Immunodeficiency Virus
HIV and Drug Use in Georgian Women
The purpose of this study is to determine how drug abuse treatment interventions can be integrated with established Human Immunodeficiency Virus prevention approaches to optimize their combined effectiveness.
- Trial name
- IMEDI (NCT01331460)
- Testing
- RBT, Case-Management
- Where
- Georgia
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill